Compare OOMA & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OOMA | ABEO |
|---|---|---|
| Founded | 2003 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 332.9M | 280.2M |
| IPO Year | 2015 | 2005 |
| Metric | OOMA | ABEO |
|---|---|---|
| Price | $13.95 | $4.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $19.00 | $18.75 |
| AVG Volume (30 Days) | 196.9K | ★ 978.0K |
| Earning Date | 06-03-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.74 |
| EPS | 0.09 | ★ 1.35 |
| Revenue | ★ $114,490,000.00 | $2,998,000.00 |
| Revenue This Year | $20.64 | N/A |
| Revenue Next Year | $3.72 | $1,589.77 |
| P/E Ratio | $156.67 | ★ $3.71 |
| Revenue Growth | 9.53 | ★ 258.18 |
| 52 Week Low | $9.79 | $3.93 |
| 52 Week High | $14.83 | $7.54 |
| Indicator | OOMA | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 68.05 | 43.97 |
| Support Level | $10.95 | $4.87 |
| Resistance Level | $14.83 | $5.60 |
| Average True Range (ATR) | 0.46 | 0.20 |
| MACD | 0.18 | -0.01 |
| Stochastic Oscillator | 75.57 | 22.97 |
Ooma Inc is a communications services company. It is a smart software-as-a-service (SaaS) and unified communications platform that deliver voice and collaboration features including messaging, intelligent virtual attendants and video conferencing, and residential phone service provides PureVoice high-definition voice quality, advanced functionality and integration with mobile devices. Its services rely upon the following main elements: multi-tenant cloud service, on-premise devices, desktop and mobile applications, and calling platforms. It generates revenues from the sale of subscriptions and other services.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.